Brazikumab - Allergan

Drug Profile

Brazikumab - Allergan

Alternative Names: AMG-139; Anti-IL-23 MAb - Amgen; MEDI-2070

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease
  • No development reported Psoriasis

Most Recent Events

  • 29 Jan 2018 Allergan and MedImmune completes phase-II clinical trials in Crohn's disease in France, Canada, Belgium, Bulgaria, Australia, USA, Germany, Czech Republic, Hungary, Israel, Italy, Netherlands, Russia, Spain (IV) (SC) (NCT02574637)
  • 01 Dec 2016 AstraZeneca completes a phase IIa trial for Crohn's disease in USA, Canada, France, Italy, Poland, Germany, Czech Republic, Hungary and Spain (NCT01714726)
  • 03 Oct 2016 Brazikumab licensed to Allergan worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top